secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001437749-24-009686
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar reports Q4/FY2023 net loss of $1.8M/$8.4M; MNPR-101 Phase 1 dosimetry trial to start
--------------------------------------------------------------------------------

- Cash, equivalents and short-term investments $7.3M at Dec. 31, 2023; plus $3.2M from Q1 2024 ATM; runway through June 30, 2025.
- Net loss Q4 2023: $1.8M ($0.12/shr) vs $2.9M ($0.22/shr) in Q4 2022; FY 2023: $8.4M ($0.61/shr) vs $10.5M ($0.83/shr) in FY 2022.
- R&D expenses fell to $1.0M in Q4 2023 ($2.1M Q4 2022) and $5.6M for FY 2023 ($7.6M FY 2022), driven by Validive cost reductions.
- MNPR-101-Zr Phase 1 dosimetry trial cleared by HREC in Australia; lead investigator Professor Rodney Hicks; enrollment imminent.
- Preclinical data: MNPR-101-Ac-225 caused near-complete tumor elimination in triple-negative breast xenograft model after single dose.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924009686/0001437749-24-009686-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924009686/mnpr20240325_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-009686

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer